In mice with lung, prostate, or ovarian cancer xenografts, either the genetic or the pharmacological inhibition of SREBP and ACLY has been shown to significantly suppress tumor growth and induce cancer cell death (Hatzivassiliou et al., 2005; Hanai et al., 2013; Cheng et al., 2018), making SREBP and/or ACLY promising therapeutic targets (Infantino et al., 2007; Guo et al., 2009; Williams et al., 2013; Li et al., 2014; Geng et al., 2016). Here, ACLY is linked to ovarian cancer.